In OVX females, the lack of estrogens fosters NAFLD development and progression by boosting pro-inflammatory response (e.g., TNFα, IL-1β and IL-6), and decreasing antioxidant defense and anti-inflammatory response (e.g., IL-10, interleukin 10), all changes that can be rescued or, at least, limited by estrogen therapy [369,370,371]. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.